PCM
BCRX icon

Prelude Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Prelude Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,897
Closed -$546K – 1149
2025
Q2 		$546K Sell
60,897
-39,003
-39% -$363K 0.05% 412
2025
Q1 		$749K Buy
+99,900
New +$806K 0.06% 385
2024
Q4 		– Sell
-38,900
Closed -$296K – 1226
2024
Q3 		$296K Buy
+38,900
New +$296K 0.02% 873
2020
Q2 		– Sell
-24,433
Closed -$97.6K – 1957
2020
Q1 		$49K Buy
+24,433
New +$67.3K ﹤0.01% 759
2019
Q3 		– Sell
-3,587
Closed -$14K – 1708
2019
Q2 		$14K Buy
+3,587
New +$21.6K ﹤0.01% 1337
2018
Q4 		– Sell
-1,318
Closed -$10K – 1781
2018
Q3 		$10K Buy
+1,318
New +$8.85K ﹤0.01% 1451
2017
Q2 		– Sell
-800
Closed -$7K – 1607
2017
Q1 		$7K Buy
+800
New +$5.57K ﹤0.01% 1387
2016
Q3 		– Sell
-24,700
Closed -$70K – 1589
2016
Q2 		$70K Buy
24,700
+18,700
+312% +$58.1K 0.01% 883
2016
Q1 		$17K Buy
+6,000
New +$26.6K ﹤0.01% 1132
2015
Q2 		– Sell
-800
Closed -$7K – 1700
2015
Q1 		$7K Sell
800
-3,700
-82% -$38.3K ﹤0.01% 1847
2014
Q4 		$55K Buy
4,500
+1,200
+36% +$13.3K 0.01% 1200
2014
Q3 		$32K Buy
3,300
+700
+27% +$8.58K ﹤0.01% 1616
2014
Q2 		$33K Buy
+2,600
New +$25.3K ﹤0.01% 1605

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's BCRX Position: Q3 2025 in Review

Prelude Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 60,897 shares — an estimated $546K sold.

Prelude Capital Management first reported a position in BCRX in Q2 2014 and held it in 13 quarters. The position peaked at $749K in Q1 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Prelude Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 60,897 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $546K.
  • Prelude Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 13 quarters.
  • Prelude Capital Management's BioCryst Pharmaceuticals position peaked at $749K in Q1 2025.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.